| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Daunorubicins/Doxorubicins; Topoisomerase II
|
|---|---|
| ln Vitro |
In Ehrlich ascites tumor cells, both sensitive and resistant, daunorubicin citrate (0-256 μg/mL, 30 minutes) suppresses DNA and RNA production [2]. In Molt-4 and L3.6 cells, daunorubicin citrate (7 nM-1.9 μM, 72 hours) demonstrates chemosensitivity [3][4]. Induction of necrosis and apoptosis in L3.6 cells is achieved by daunorubicin citrate (0.4 μM) for 48 hours. Induction of ROS generation in L3.6 cells is achieved by daunorubicin citrate (0.4 μM) for 120 minutes (2). K562 cells, a myeloid cell line, undergo autophagy in response to daunorubicin citrate (2 μM) for a 24-hour period [6].
|
| ln Vivo |
Rats administered daunorubicin citrate (intravenous injection, 3 mg/kg, three times, 48 hours apart) develop nephrotoxicity and cardiotoxicity [5]. In mice, sister chromatid exchange is induced by intraperitoneal injection of daunorubicin citrate at a dose of 10 mg/kg [7].
|
| Enzyme Assay |
Daunorubicin inhibits of both DNA and RNA syntheses in HeLa cells over a concentration range of 0.2 through 2 μM.
|
| Cell Assay |
Cell viability assay[3][4]
Cell Types: Molt-4 cells (human T lymphocytic leukemia cell line), L3.6 cells (metastatic human pancreatic cell line) Tested Concentrations: 7 nM-1.9 μM Incubation Duration: 72 hrs (hours) Experimental Results: Inhibited cell viability with IC50 values of 40 nM (Molt-4) and 400 nM (L3.6). Apoptosis analysis [4] Cell Types: L3.6 Cell Tested Concentrations: 0.4 μM Incubation Duration: 24 h, 48 h Experimental Results: 24 h induced necrosis without apoptosis, 48 h induced apoptosis and extensive necrosis reaction. Western Blot Analysis [6] Cell Types: K562 cells Tested Concentrations: 2 μM Incubation Duration: 24 h Experimental Results: LC3-I was converted into LC3-II, accompanied by a significant increase in LC3 expression level. |
| Animal Protocol |
Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat [5]
Doses: 3 mg/kg Route of Administration: intravenous (iv) (iv)injection, 3 times, 48 hrs (hrs (hours)) apart. Experimental Results: It resulted in a significant increase in MDA (malondialdehyde) levels in renal tissue and a significant decrease in total GPx activity. Urinary protein excretion, serum creatinine, and BUN levels increased. |
| References |
|
| Additional Infomation |
Daunorubicin Citrate is a semi-synthetic anthracycline glycoside antibiotic obtained from Streptomyces with antineoplastic activity. Daunorubicin citrate intercalates DNA, which leads to inhibition of DNA and RNA synthesis, and consequently blocks cell division and results in apoptosis. This anti-tumor antibiotic is most active in the S phase of cell division. Daunorubicin is indicated in the treatment of a wide variety of cancers including acute non-lymphocytic leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor, and chronic myelocytic leukemia. (NCI05)
|
| Molecular Formula |
C33H37NO17
|
|---|---|
| Molecular Weight |
719.64
|
| Exact Mass |
719.206
|
| Elemental Analysis |
C, 55.08; H, 5.18; N, 1.95; O, 37.79
|
| CAS # |
1884557-85-0
|
| Related CAS # |
Daunorubicin hydrochloride;23541-50-6;Daunorubicin;20830-81-3
|
| PubChem CID |
9961878
|
| Appearance |
Solid powder
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
51
|
| Complexity |
1190
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
|
| InChi Key |
VNTHYLVDGVBPOU-QQYBVWGSSA-N
|
| InChi Code |
InChI=1S/C27H29NO10.C6H8O7/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t10-,14-,16-,17-,22+,27-;/m0./s1
|
| Chemical Name |
(8S,10S)-8-acetyl-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione 2-hydroxypropane-1,2,3-tricarboxylate
|
| Synonyms |
Daunoxome
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: > 10 mM
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3896 mL | 6.9479 mL | 13.8958 mL | |
| 5 mM | 0.2779 mL | 1.3896 mL | 2.7792 mL | |
| 10 mM | 0.1390 mL | 0.6948 mL | 1.3896 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
